Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for  month after the last dose of study drug; for males, these restrictions apply for  months after the last dose of study drug
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for sexually active women of childbearing potential, these restrictions apply for  months after the last dose of study drug; for sexually active men, these restrictions apply for  months after the last dose of study drug
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for  month after the last dose of study drug; for males, these restrictions apply for  months after the last dose of study drug
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for  months after last dose of obinutuzumab, or  month after the last dose of ibrutinib, whichever is later; for males, these restrictions apply for  months after the last dose of obinutuzumab or  months after the last dose of ibrutinib, whichever is later
Women of childbearing potential and men who are sexually active with a woman of childbearing potential must be practicing a highly effective method of birth control during and after the study ( months for women and  months for men), consistent with local regulations regarding the use of birth control methods for subjects participating in this clinical study; men must agree to not donate sperm during and for up to  months after their conclusion of therapy on study
Women of childbearing potential and men who are sexually active must affirm they are practicing a highly effective method of barrier birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during or after the study; these restrictions apply throughout the treatment period and for three months after the last dose of enzalutamide
Women of childbearing potential and men who are sexually active must affirm they are practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during or after the study; for females, these restrictions apply for  month after the last dose of study drug; for males, these restrictions apply for  months after the last dose of the study drug
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trial; men must agree to not donate sperm during and after the study\r\n* For females, these restrictions apply for  month after the last dose of study drug; for males, these restrictions apply for  months after the last dose of study drug
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study; females of childbearing potential: must either completely abstain from heterosexual sexual conduct or must use  methods of reliable contraception,  highly effective (intrauterine device, birth control pills, hormonal patches, injections, vaginal rings, or implants) and at least  additional method (condom, diaphragm, cervical cap) of birth control; reliable contraceptive methods must be started at least  weeks before lenalidomide; males who are sexually active must be practicing complete abstinence or agree to a condom during sexual contact with a pregnant female or female of child bearing potential; men must agree to not donate sperm during and after the study; for females, these restrictions apply at least  weeks before study treatment, during the period of therapy and for  month after the last dose of study drug; for males, these restrictions apply during the period of therapy and for  months after the last dose of study drug
Agrees to protocol-defined use of effective contraception (for women, these restrictions apply for  months after the last dose of rituximab or  month after the last dose of study drug, whichever is later; for men, these restrictions apply for  months after the last dose of rituximab or  months after the last dose of study drug, whichever is later)
Women of childbearing potential and men who are sexually active must affirm they are practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during or after the study; for females, these restrictions apply for  month after the last dose of study drug; for males, these restrictions apply for  months after the last dose of the study drug
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for women, these restrictions apply for  month after the last dose of study drug; for men, these restrictions apply for  months after the last dose of study drug
Any of the following:\r\n* Pregnant persons\r\n* Nursing persons\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception; Note: persons of childbearing potential and persons able to father a child who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; subjects must agree to not donate sperm during and after the study; for persons of childbearing potential, these restrictions apply for  month after the last dose of study drug; for persons able to father a child, these restrictions apply for  months after the last dose of study drug
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for  months after the last dose of ibrutinib and  month after the last dose of nivolumab; for males, these restrictions apply for  month after the last dose of study drugs
Women of childbearing potential and men who are sexually active with a woman of childbearing potential must be practicing a highly effective method of birth control during and after the study ( months for women and  months for men), consistent with local regulations regarding the use of birth control methods for subjects participating in this clinical study
Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for  month after the last dose of study drug; for males, these restrictions apply for  months after the last dose of study drug
